Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy
Jia Jia1, Lili Mao2, Jing Lin3, Wenyu Li2, Pei Yuan1, Lei Guo1, Jie Dai2, Caili Li2, Xue Bai2, Zhongwu Li4, Yu Chen3, Jun Guo2, Jianming Ying1(), Lu Si2()
1. State Key Laboratory of Molecular Oncology, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China 2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing 100142, China 3. Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China 4. Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, China
SH Jeong, JH Hyeong, EJ Park, KJ Kim, KH Kim. Human epidermal growth factor receptor 2 expression in extramammary Paget’s disease and mammary Paget’s disease. Australas J Dermatol 2022; 63(1): 115–118 https://doi.org/10.1111/ajd.13782
2
G Angelico, A Santoro, F Inzani, P Straccia, D Arciuolo, A Mulè, M Valente, S Spadola, N D’Alessandris, G Garganese, F Cianfrini, A Piermattei, G Scambia, GF Zannoni. Hormonal environment and HER2 status in extra-mammary Paget’s disease (eMPD): a systematic literature review and meta-analysis with clinical considerations. Diagnostics (Basel) 2020; 10(12): 1040 https://doi.org/10.3390/diagnostics10121040
3
N Sekiguchi, S Kubota, T Noguchi, T Fukushima, T Kobayashi, S Kanda, T Koizumi, T Miyake, T Shirai, R Okuyama. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget’s disease: four cases and a review. J Dermatol 2020; 47(11): 1276–1279 https://doi.org/10.1111/1346-8138.15515
4
National Medical Products Administration. Disitamab vedotin: NMPA Approval notice. 2021, available from the website of NMPA
5
RemeGen. Disitamab vedotin: Chinese prescribing information. Yantai. 2021
6
J Wang, Y Liu, Q Zhang, J Feng, J Fang, X Chen, Y Han, Q Li, P Zhang, P Yuan, F Ma, Y Luo, Y Fan, R Cai, S Chen, Q Li, Y Li, B Xu. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. J Clin Oncol 2021; 39(15 Suppl): 1022 (abstract no. 1022) https://doi.org/10.1200/JCO.2021.39.15_suppl.1022
7
Y Xu, Y Wang, J Gong, X Zhang, Z Peng, X Sheng, C Mao, Q Fan, Y Bai, Y Ba, D Jiang, F Yang, C Qi, J Li, X Wang, J Zhou, M Lu, Y Cao, J Yuan, D Liu, Z Wang, J Fang, L Shen. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021; 24(4): 913–925 https://doi.org/10.1007/s10120-021-01168-7
8
E Zattarin, F Nichetti, F Ligorio, L Mazzeo, R Lobefaro, G Fucà, G Peverelli, A Vingiani, GV Bianchi, G Capri, Braud F de, C Vernieri. Case Report: prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. Front Oncol 2022; 12: 925551 https://doi.org/10.3389/fonc.2022.925551
9
DS Shin, T Sherry, ME Kallen, S Wong, A Drakaki. Human epidermal growth factor receptor 2 (HER-2/neu)-directed therapy for rare metastatic epithelial tumors with HER-2 amplification. Case Rep Oncol 2016; 9(2): 298–304 https://doi.org/10.1159/000445827
10
K Tokuchi, T Maeda, S Kitamura, T Yanagi, H Ujiie. HER2-targeted antibody-drug conjugates display potent antitumor activities in preclinical extramammary Paget’s disease models: in vivo and immunohistochemical analyses. Cancers (Basel) 2022; 14(14): 3519 https://doi.org/10.3390/cancers14143519
